BOSTON, Massachusetts, Sept. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Dana-Farber researchers find blood test could guide future treatment in Ewing sarcoma

*

Prospective national study validates circulating tumor DNA as a predictor of relapse risk and identifies low-, intermediate-, and high-risk patient groups

A blood test may help doctors identify which patients with . . .

Click here for more information about our products